Synonyms
Inherited Variability of Drug Response; Pharmacogenetics of NSAIDs
Definition
Pharmacogenetics seeks to explore how genetic variants influence the pharmacokinetic and pharmacodynamic properties of a given drug, by determining how mutations in the genes that encode drug metabolizing enzymes, drug targets and drug transporters influence drug response.
Characteristics
Nonsteroidal anti-inflammatory drugs (NSAID) block the formation of prostaglandins by inhibiting the rate-limiting cyclooxygenase (COX) enzymes, COX–1 and COX–2, also known as prostaglandin H2synthases (PGHS1 and PGHS2). Since prostaglandins participate in mediating the inflammatory response, the pharmacological activity of NSAIDs consists mainly of antinociceptive, anti-inflammatory and antipyretic properties. Variations of this pharmacological activity can arise as a basic principle from mutations in proteins, which (i) influence the bioavailability of a drug, (ii) vary the binding affinity to the drug target,...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aithal GP, Day CP, Leathart JB et al. (2000) Relationship of Polymorphism in CYP2C9 to Genetic Susceptibility to Diclofenac-Induced Hepatitis. Pharmacogenetics 10:511–518
Baillie TA, Halpin RA, Matuszewski BK et al. (2001) Mechanistic Studies on the Reversible Metabolism of Rofecoxib to 5-Hydroxyrofecoxib in the Rat: Evidence for Transient Ring Opening of a Substituted 2-Furanone Derivative using Stable Isotope-Labeling Techniques. Drug Metab Dispos 29:1614–1628
Garcia-Martin E, Martinez C, Tabares B et al. (2004) Interindividual Variability in Ibuprofen Pharmacokinetics is Related to Interaction of Cytochrome P450 2C8 and 2C9 Amino Acid Polymorphisms. Clin Pharmacol Ther 76:119–127
Gunnarsson I, Kanerud L, Pettersson E et al. (1997) Predisposing Factors in Sulphasalazine-Induced Systemic Lupus Erythematosus. Br J Rheumatol 36:1089–1094
Halushka MK, Walker LP, Halushka PV (2003) Genetic Variation in Cyclooxygenase 1: Effects on Response to Aspirin. Clin Pharmacol Ther 73:122–130
Karim A, Tolbert D, Piergies A et al. (2000) Celecoxib does not Significantly Alter the Pharmacokinetics or Hypoprothrombinemic Effect of Warfarin in Healthy Subjects. J Clin Pharmacol 40:655–663
Kirchheiner J, Meineke I, Freytag G et al. (2002) Enantiospecific Effects of Cytochrome P450 2C9 Amino Acid Variants on Ibuprofen Pharmacokinetics and on the Inhibition of Cyclooxygenases 1 and 2. Clin Pharmacol Ther 72:62–75
Kirchheiner J, Stormer E, Meisel C et al. (2003) Influence of CYP2C9 Genetic Polymorphisms on Pharmacokinetics of Celecoxib and its Metabolites. Pharmacogenetics 13:473–480
Lee CR, Pieper JA, Frye RF et al. (2003) Differences in Flurbiprofen Pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 Genotypes. Eur J Clin Pharmacol 58:791–794
Malhi H, Atac B, Daly AK et al. (2004) Warfarin and Celecoxib Interaction in the Setting of Cytochrome P450 (CYP2C9) Polymorphism with Bleeding Complication. Postgrad Med J 80:107–109
Ohtani, T., A. Hiroi, M. Sakurane and F. Furukawa (2003) Slow Acetylator Genotypes as a Possible Risk Factor for Infectious Mononucleosis-Like Syndrome Induced by Salazosulfapyridine. Br J Dermatol 148:1035–1039
Papafili A, Hill MR, Brull DJ et al. (2002) Common Promoter Variant in Cyclooxygenase-2 Represses Gene Expression: Evidence of Role in Acute-Phase Inflammatory Response. Arterioscler Thromb Vasc Biol 22:1631–1636
Sabbagh N, Delaporte E, Marez D et al. 1997) NAT2 Genoty** and Efficacy of Sulfasalazine in Patients with Chronic Discoid Lupus Erythematosus. Pharmacogenetics 7:131–135
Sanak M, Pierzchalska M, Bazan-Socha S et al. (2000) Enhanced Expression of the Leukotriene C(4) Synthase due to Overactive Transcription of an Allelic Variant Associated with Aspirin-Intolerant Asthma. Am J Respir Cell Mol Biol 23:290–296
Sanak M, Simon HU, Szczeklik A (1997) Leukotriene C4 Synthase Promoter Polymorphism and Risk of Aspirin-Induced Asthma. Lancet 350:1599–1600
Szczeklik W, Sanak M, Szczeklik A (2004) Functional Effects and Gender Association of COX–2 Gene Polymorphism G-765C in Bronchial Asthma. J Allergy Clin Immunol 114:248–253
Tanigawara Y, Kita T, Aoyama N et al. (2002) N-acetyltransferase 2 Genotype-Related Sulfapyridine Acetylation and its Adverse Events. Biol Pharm Bull 25:1058–1062
Ulrich CM, Bigler J, Sibert J et al. (2002) Cyclooxygenase-1 (COX1) Polymorphisms in African-American and Caucasian Populations. Hum Mutat 20:409–410
Werner U, Werner D, Rau T et al. (2003) Celecoxib Inhibits Metabolism of Cytochrome P450 2D6 Substrate Metoprolol in Humans. Clin Pharmacol Ther 74:130–137
Yasar U, Lundgren S, Eliasson E et al. (2002) Linkage between the CYP2C8 and CYP2C9 Genetic Polymorphisms. Biochem Biophys Res Commun 299:25–28
Yazdanian M, Briggs K, Jankovsky C et al. 2004) The “High Solubility” Definition of the Current FDA Guidance on Biopharmaceutical Classification System may be too Strict for Acidic Drugs. Pharm Res 21:293–299
Zhang JY, Zhan J, Cook CS et al. (2003) Involvement of Human UGT2B7 and 2B15 in Rofecoxib Metabolism. Drug Metab Dispos 31:652–658
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Skarke, C. (2007). NSAIDs, Pharmacogenetics. In: Schmidt, R., Willis, W. (eds) Encyclopedia of Pain. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-29805-2_2852
Download citation
DOI: https://doi.org/10.1007/978-3-540-29805-2_2852
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-43957-8
Online ISBN: 978-3-540-29805-2
eBook Packages: MedicineReference Module Medicine